1. Cancer drugs for hepatitis B treatment: what do we know?. (September 2015) Authors: Ebert, Gregor; Pellegrini, Marc Journal: Future virology Issue: Volume 10:Number 9(2015) Page Start: 1025 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Mechanism and inhibition of the papain‐like protease, PLpro, of SARS‐CoV‐2. (26th August 2020) Authors: Klemm, Theresa; Ebert, Gregor; Calleja, Dale J; Allison, Cody C; Richardson, Lachlan W; Bernardini, Jonathan P; Lu, Bernadine GC; Kuchel, Nathan W; Grohmann, Christoph; Shibata, Yuri; Gan, Zhong Yan; Cooney, James P; Doerflinger, Marcel; Au, Amanda E; Blackmore, Timothy R; van der Heden van Noort... Journal: EMBO journal Issue: Volume 39:Number 18(2020) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Targeted protein degradation at the host–pathogen interface. Issue 3 (2nd December 2021) Authors: Grohmann, Christoph; Marapana, Danushka S.; Ebert, Gregor Other Names: Hartland Elizabeth guestEditor. Journal: Molecular microbiology Issue: Volume 117:Issue 3(2022) Page Start: 670 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. The role of tumour necrosis factor in hepatitis B infection: Jekyll and Hyde. Issue 12 (9th December 2016) Authors: Valaydon, Zina; Pellegrini, Marc; Thompson, Alexander; Desmond, Paul; Revill, Peter; Ebert, Gregor Journal: Clinical & translational immunology Issue: Volume 5:Issue 12 (2016) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗